Post-Translational Modification Enzymes: How to Interrogate Key Drug Targets
Post-Translational Modification Enzymes: How to Interrogate Key Drug Targets
Promega have developed a detection technology platform highly suitable to screening of PTM enzymatic activities. In this webinar Promega will demonstrate how cellular mechanisms driven by PTM can be addressed by analyzing the biochemical activities of the involved enzymes using a simple suite of bioluminescent nucleotide detection assays.
In this webinar Promega will:
• Review posttranslational modifications and their role in cell health
• See examples of PTM dysregulation and results
• Examine a new bioluminescent nucleotide detection assay platform suitable to screening PTM enzyme activities
Learn about the role of PTMs and their enzyme partners in cell health and dysfunction, and see how to interrogate cellular mechanisms driven by PTMs by analyzing the biochemical activities of unique PTM enzymes with a bioluminescent nucleotide detection assays.
Speaker Bio
Dr. Hicham Zegzouti is a Senior Research Scientist in Promega Assay Design-R&D. His group develops Assay technologies to interrogate diverse enzyme activities and cellular pathways (kinases, glycosyltransferases, and other drug targets). Dr. Zegzouti received his PhD in 1997 from the National Polytechnic Institute of Toulouse, France. Prior to joining Promega, he was a postdoctoral researcher in Molecular, Cell and Developmental Biology at UC-Los Angeles studying auxin hormone signaling in an Arabidopsis plant model. His work focused on the identification and characterization of AGC kinase family and its regulation during plant development. Dr. Zegzouti has authored 14 journal articles and book chapters, co-edited a methods book and is an inventor for one issued and 4 pending patents.
Tuesday, April 11, 2017
Multiple Webinar Times Available
Duration: 1 hour